Symposium review: high altitude travel with pulmonary vascular disease.
altitude‐related adverse events
chronic thromboembolic pulmonary hypertension altitude
high altitude travel
hypoxia
pulmonary arterial hypertension
pulmonary hypertension
Journal
The Journal of physiology
ISSN: 1469-7793
Titre abrégé: J Physiol
Pays: England
ID NLM: 0266262
Informations de publication
Date de publication:
23 May 2024
23 May 2024
Historique:
received:
18
06
2023
accepted:
26
04
2024
medline:
23
5
2024
pubmed:
23
5
2024
entrez:
23
5
2024
Statut:
aheadofprint
Résumé
Pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension are the main precapillary forms of pulmonary hypertension (PH) summarized as pulmonary vascular diseases (PVD). PVDs are characterized by exertional dyspnoea and oxygen desaturation, and reduced quality of life and survival. Medical therapies improve life expectancy and physical performance of PVD patients, of whom many wish to participate in professional work and recreational activities including traveling to high altitude. The exposure to the hypobaric hypoxic environment of mountain regions incurs the risk of high altitude adverse events (AE
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Author(s). The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society.
Références
Albert, T. J., & Swenson, E. R. (2014). Peripheral chemoreceptor responsiveness and hypoxic pulmonary vasoconstriction in humans. High Altitude Medicine & Biology, 15(1), 15–20.
Bauer, M., Muller, J., Schneider, S. R., Buenzli, S., Furian, M., Ulrich, T., Carta, A. F., Bader, P. R., Lichtblau, M., Taalaibekova, A., Raimberdiev, M., Champigneulle, B., Sooronbaev, T., Bloch, K. E., & Ulrich, S. (2023). Hypoxia‐altitude simulation test to predict altitude‐related adverse health effects in COPD patients. ERJ Open Research, 9(2), 00488–2022.
Bradford, J. R., & Dean, H. P. (1894). The pulmonary circulation. The Journal of Physiology, 16, 34–158.2515825.
Carta, A. F., Lichtblau, M., Berlier, C., Saxer, S., Schneider, S. R., Schwarz, E. I., Furian, M., Bloch, K. E., & Ulrich, S. (2022). The impact of breathing hypoxic gas and oxygen on pulmonary hemodynamics in patients with pulmonary hypertension. Frontiers in Medicine, 9, 791423.
Cenedese, E., Speich, R., Dorschner, L., Ulrich, S., Maggiorini, M., Jenni, R., & Fischler, M. (2006). Measurement of quality of life in pulmonary hypertension and its significance. European Respiratory Journal, 28(4), 808–815.
Coker, R. K., Armstrong, A., Church, A. C., Holmes, S., Naylor, J., Pike, K., Saunders, P., Spurling, K. J., & Vaughn, P. (2022). BTS clinical statement on air travel for passengers with respiratory disease. Thorax, 77(4), 329–350.
De Canniere, D., Stefanidis, C., Hallemans, R., Delcroix, M., Brimioulle, S., & Naeije, R. (1992). Stimulus‐response curves for hypoxic pulmonary vasoconstriction in piglets. Cardiovascular Research, 26(10), 944–949.
Dunham‐Snary, K. J., Wu, D., Sykes, E. A., Thakrar, A., Parlow, L. R. G., Mewburn, J. D., Parlow, J. L., & Archer, S. L. (2017). Hypoxic pulmonary vasoconstriction: From molecular mechanisms to medicine. Chest, 151(1), 181–192.
Faoro, V., Boldingh, S., Moreels, M., Martinez, S., Lamotte, M., Unger, P., Brimioulle, S., Huez, S., & Naeije, R. (2009). Bosentan decreases pulmonary vascular resistance and improves exercise capacity in acute hypoxia. Chest, 135(5), 1215–1222.
Faoro, V., Lamotte, M., Deboeck, G., Pavelescu, A., Huez, S., Guenard, H., Martinot, J. B., & Naeije, R. (2007). Effects of sildenafil on exercise capacity in hypoxic normal subjects. High Altitude Medicine & Biology, 8(2), 155–163.
Furian, M., Mademilov, M., Buergin, A., Scheiwiller, P. M., Mayer, L., Schneider, S., Emilov, B., Lichtblau, M., Bitos, K., Muralt, L., Groth, A., Reiser, A. E., Sevik, A., Sheraliev, U., Marazhapov, N. H., Aydaralieva, S., Muratbekova, A., Tabyshova, A., Abdraeva, A., … Bloch, K. E. (2022). Acetazolamide to prevent adverse altitude effects in COPD and healthy adults. NEJM Evidence, 1(1), EVIDoa2100006.
Ghofrani, H. A., Reichenberger, F., Kohstall, M. G., Mrosek, E. H., Seeger, T., Olschewski, H., Seeger, W., & Grimminger, F. (2004). Sildenafil increased exercise capacity during hypoxia at low altitudes and at Mount Everest base camp: A randomized, double‐blind, placebo‐controlled crossover trial. Annals of Internal Medicine, 141(3), 169–177.
Groth, A., Saxer, S., Bader, P. R., Lichtblau, M., Furian, M., Schneider, S. R., Schwarz, E. I., Bloch, K. E., & Ulrich, S. (2018). Acute hemodynamic changes by breathing hypoxic and hyperoxic gas mixtures in pulmonary arterial and chronic thromboembolic pulmonary hypertension. International Journal of Cardiology, 270, 262–267.
Grunig, E., Dehnert, C., Mereles, D., Koehler, R., Olschewski, H., Bartsch, P., & Janssen, B. (2005). Enhanced hypoxic pulmonary vasoconstriction in families of adults or children with idiopathic pulmonary arterial hypertension. Chest, 128, (6 Suppl), 630S–633S.
Hampson, N. B., Kregenow, D. A., Mahoney, A. M., Kirtland, S. H., Horan, K. L., Holm, J. R., & Gerbino, A. J. (2013). Altitude exposures during commercial flight: A reappraisal. Aviation Space and Environmental Medicine, 84(1), 27–31.
Hildenbrand, F. F., Bloch, K. E., Speich, R., & Ulrich, S. (2012). Daytime measurements underestimate nocturnal oxygen desaturations in pulmonary arterial and chronic thromboembolic pulmonary hypertension. Respiration, 84(6), 477–484.
Hildenbrand, F. F., Fauchere, I., Huber, L. C., Keusch, S., Speich, R., & Ulrich, S. (2012). A low resting heart rate at diagnosis predicts favourable long‐term outcome in pulmonary arterial and chronic thromboembolic pulmonary hypertension. A prospective observational study. Respiratory Research, 13(1), 76.
Humbert, M., Kovacs, G., Hoeper, M. M., Badagliacca, R., Berger, R. M. F., Brida, M., Carlsen, J., Coats, A. J. S., Escribano‐Subias, P., Ferrari, P., Ferreira, D. S., Ghofrani, H. A., Giannakoulas, G., Kiely, D. G., Mayer, E., Meszaros, G., Nagavci, B., Olsson, K. M., Pepke‐Zaba, J., … ESC/ERS Scientific Document Group. (2022). 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. European Respiratory Journal, 43(38), 3618–3731.
Jensen, K. S., Micco, A. J., Czartolomna, J., Latham, L., & Voelkel, N. F. (1992). Rapid onset of hypoxic vasoconstriction in isolated lungs. Journal of Applied Physiology, 72(5), 2018–2023.
Kylhammar, D., & Radegran, G. (2017). The principal pathways involved in the in vivo modulation of hypoxic pulmonary vasoconstriction, pulmonary arterial remodelling and pulmonary hypertension. Acta Physiologica, 219(4), 728–756.
Leon‐Velarde, F., Maggiorini, M., Reeves, J. T., Aldashev, A., Asmus, I., Bernardi, L., Ge, R. L., Hackett, P., Kobayashi, T., Moore, L. G., Penaloza, D., Richalet, J. P., Roach, R., Wu, T., Vargas, E., Zubieta‐Castillo, G., & Zubieta‐Calleja, G. (2005). Consensus statement on chronic and subacute high altitude diseases. High Altitude Medicine & Biology, 6(2), 147–157.
Lichtblau, M., Saxer, S., Furian, M., Mayer, L., Bader, P. R., Scheiwiller, P. M., Mademilov, M., Sheraliev, U., Tanner, F. C., Sooronbaev, T. M., Bloch, K. E., & Ulrich, S. (2020). Cardiac function and pulmonary hypertension in Central Asian highlanders at 3250 m. European Respiratory Journal, 56(2), 1902474.
Lichtblau, M., Saxer, S., Latshang, T. D., Aeschbacher, S. S., Huber, F., Scheiwiller, P. M., Herzig, J. J., Schneider, S. R., Hasler, E. D., Furian, M., Bloch, K. E., Ulrich, S. (2020). Altitude travel in patients with pulmonary hypertension: Randomized pilot‐trial evaluating nocturnal oxygen therapy. Frontiers in Medicine (Lausanne), 7, 502.
Luks, A. M., & Hackett, P. H. (2022). Medical conditions and high‐altitude travel. New England Journal of Medicine, 386(4), 364–373.
Maggiorini, M. (2010). Prevention and treatment of high‐altitude pulmonary edema. Progress in Cardiovascular Diseases, 52(6), 500–506.
Maggiorini, M., Brunner‐La Rocca, H. P., Peth, S., Fischler, M., Bohm, T., Bernheim, A., Kiencke, S., Bloch, K. E., Dehnert, C., Naeije, R., Lehmann, T., Bartsch, P., & Mairbaurl, H. (2006). Both tadalafil and dexamethasone may reduce the incidence of high‐altitude pulmonary edema: a randomized trial. Annals of Internal Medicine, 145(7), 497–506.
Mallet, R. T., Burtscher, J., Richalet, J. P., Millet, G. P., & Burtscher, M. (2021). Impact of high altitude on cardiovascular health: Current perspectives. Vascular Health and Risk Management, 17, 317–335.
Marshall, C., & Marshall, B. (1983). Site and sensitivity for stimulation of hypoxic pulmonary vasoconstriction. Journal of Applied Physiology: Respiratory, Environmental and Exercise Physiology, 55(3), 711–716.
McGoon, M. D., Ferrari, P., Armstrong, I., Denis, M., Howard, L. S., Lowe, G., Mehta, S., Murakami, N., & Wong, B. A. (2019). The importance of patient perspectives in pulmonary hypertension. European Respiratory Journal, 53(1), 1801919.
Muller, J., Titz, A., Schneider, S. R., Bauer, M., Mayer, L., Luond, L., Ulrich, T., Furian, M., Forrer, A., Schwarz, E. I., Bloch, K. E., Lichtblau, M., & Ulrich, S. (2024). The effect of high altitude (2500 m) on incremental cycling exercise in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: A randomised controlled crossover trial. European Respiratory Journal, 63(3), 301001.
Oka, M., Homma, N., Taraseviciene‐Stewart, L., Morris, K. G., Kraskauskas, D., Burns, N., Voelkel, N. F., & McMurtry, I. F. (2007). Rho kinase‐mediated vasoconstriction is important in severe occlusive pulmonary arterial hypertension in rats. Circulation Research, 100(6), 923–929.
Olschewski, H., Behr, J., Bremer, H., Claussen, M., Douschan, P., Halank, M., Held, M., Hoeper, M. M., Holt, S., Klose, H., Kruger, S., Lange, T. J., Reichenberger, F., Skowasch, D., Ulrich, S., Wilkens, H., & Seeger, W. (2018). Pulmonary hypertension due to lung diseases: Updated recommendations from the Cologne Consensus Conference 2018. International Journal of Cardiology, 272S, 63–68.
Penaloza, D., & Arias‐Stella, J. (2007). The heart and pulmonary circulation at high altitudes: Healthy highlanders and chronic mountain sickness. Circulation, 115(9), 1132–1146.
Pham, I., Wuerzner, G., Richalet, J. P., Peyrard, S., & Azizi, M. (2012). Bosentan effects in hypoxic pulmonary vasoconstriction: Preliminary study in subjects with or without high altitude pulmonary edema‐history. Pulmonary Circulation, 2(1), 28–33.
Reeves, J. T., Wagner, W. W. Jr., McMurtry, I. F., & Grover, R. F. (1979). Physiological effects of high altitude on the pulmonary circulation. International Review of Physiology, 20, 289–310.
Roubinian, N., Elliott, C. G., Barnett, C. F., Blanc, P. D., Chen, J., De Marco, T., & Chen, H. (2012). Effects of commercial air travel on patients with pulmonary hypertension air travel and pulmonary hypertension. Chest, 142(4), 885–892.
Saxer, S., Lichtblau, M., Berlier, C., Hasler, E. D., Schwarz, E. I., & Ulrich, S. (2019). Physical activity in incident patients with pulmonary arterial and chronic thromboembolic hypertension. Lung, 197(5), 617–625.
Schneider, S. R., Lichtblau, M., Furian, M., Mayer, L. C., Berlier, C., Muller, J., Saxer, S., Schwarz, E. I., Bloch, K. E., & Ulrich, S. (2022). Cardiorespiratory adaptation to short‐term exposure to altitude vs. normobaric hypoxia in patients with pulmonary hypertension. Journal of Clinical Medicine, 11(10), 2769.
Schneider, S. R., Mayer, L. C., Lichtblau, M., Berlier, C., Schwarz, E. I., Saxer, S., Furian, M., Bloch, K. E., & Ulrich, S. (2021). Effect of normobaric hypoxia on exercise performance in pulmonary hypertension: Randomized trial. Chest, 159(2), 757–771.
Schneider, S. R., Mayer, L. C., Lichtblau, M., Berlier, C., Schwarz, E. I., Saxer, S., Tan, L., Furian, M., Bloch, K. E., & Ulrich, S. (2021). Effect of a day‐trip to altitude (2500 m) on exercise performance in pulmonary hypertension: Randomised crossover trial. ERJ Open Research, 7(4), 00314–2021.
Schneider, S. R., Muller, J., Bauer, M., Mayer, L., Luond, L., Ulrich, T., Furian, M., Forrer, A., Carta, A., Schwarz, E. I., Bloch, K. E., Lichtblau, M., & Ulrich, S. (2024). Overnight exposure to high altitude in pulmonary hypertension: Adverse events and effect of oxygen therapy. European Heart Journal, 45(4), 309–311.
Seccombe, L. M., Chow, V., Zhao, W., Lau, E. M., Rogers, P. G., Ng, A. C., Veitch, E. M., Peters, M. J., & Kritharides, L. (2017). Right heart function during simulated altitude in patients with pulmonary arterial hypertension. Open Heart, 4(1), e000532.
Siebenmann, C., & Lundby, C. (2015). Regulation of cardiac output in hypoxia. Scandinavian Journal of Medicine & Science in Sports, 25 (Suppl 4), 53–59.
Soria, R., Egger, M., Scherrer, U., Bender, N., & Rimoldi, S. F. (2016). Pulmonary artery pressure and arterial oxygen saturation in people living at high or low altitude: systematic review and meta‐analysis. Journal of Applied Physiology, 121(5), 1151–1159.
Swenson, E. R. (2013). Hypoxic pulmonary vasoconstriction. High Altitude Medicine & Biology, 14(2), 101–110.
Thamm, M., Voswinckel, R., Tiede, H., Lendeckel, F., Grimminger, F., Seeger, W., & Ghofrani, H. A. (2011). Air travel can be safe and well tolerated in patients with clinically stable pulmonary hypertension. Pulmonary Circulation, 1(2), 239–243.
Tremblay, J. C., & Ainslie, P. N. (2021). Global and country‐level estimates of human population at high altitude. Proceedings of the National Academy of Sciences, USA, 118(18), e2102463118.
Ulrich, S., Fischler, M., Speich, R., & Bloch, K. E. (2008). Sleep‐related breathing disorders in patients with pulmonary hypertension. Chest, 133(6), 1375–1380.
Ulrich, S., Fischler, M., Speich, R., & Bloch, K. E. (2013). Wrist actigraphy predicts outcome in patients with pulmonary hypertension. Respiration, 86(1), 45–51.
Ulrich, S., Hasler, E. D., Furian, M., Saxer, S., & Bloch, K. E. (2017). Mechanisms of improved exercise performance under hyperoxia: On Haldane, Geppert, Zunz, and Eschenbacher transformations. Respiration, 94(1), 72–73.
Ulrich, S., Hasler, E. D., Saxer, S., Furian, M., Muller‐Mottet, S., Keusch, S., & Bloch, K. E. (2017). Effect of breathing oxygen‐enriched air on exercise performance in patients with precapillary pulmonary hypertension: Randomized, sham‐controlled cross‐over trial. European Heart Journal, 38(15), 1159–1168.
Ulrich, S., Lichtblau, M., Schneider, S. R., Saxer, S., & Bloch, K. E. (2022). Clinician's corner: Counseling patients with pulmonary vascular disease traveling to high altitude. High Altitude Medicine & Biology, 23(3), 201–208.
Ulrich, S., Saxer, S., Hasler, E. D., Schwarz, E. I., Schneider, S. R., Furian, M., Bader, P. R., Lichtblau, M., & Bloch, K. E. (2019). Effect of domiciliary oxygen therapy on exercise capacity and quality of life in patients with pulmonary arterial or chronic thromboembolic pulmonary hypertension: A randomised, placebo‐controlled trial. European Respiratory Journal, 54(2), 1900276.
Ulrich, S., Schneider, S. R., & Bloch, K. E. (2017). Effect of hypoxia and hyperoxia on exercise performance in healthy individuals and in patients with pulmonary hypertension: A systematic review. Journal of Applied Physiology, 123(6), 1657–1670.
Voelkel, N. F., & Gomez‐Arroyo, J. (2014). The role of vascular endothelial growth factor in pulmonary arterial hypertension. The angiogenesis paradox. American Journal of Respiratory Cell and Molecular Biology, 51(4), 474–484.
von Euler, U. S., & Liljestrand, G. (1946). Observation on the pulmonary arterial blood pressure in the cat. Acta Physiologica Scandinavica, 12, 301–320.
Zhao, L., Mason, N. A., Morrell, N. W., Kojonazarov, B., Sadykov, A., Maripov, A., Mirrakhimov, M. M., Aldashev, A., & Wilkins, M. R. (2001). Sildenafil inhibits hypoxia‐induced pulmonary hypertension. Circulation, 104(4), 424–428.